Severe cases, characterized by seizures or cerebral edema, necessitate aggressive treatment with high-dose corticosteroids, intensive care support, and cytokine inhibitors such as IL-1 receptor antagonists or siltuximab, an anti-IL-6 agent, particularly when cytokine release syndrome (CRS) is present [21,22]. This evidence concerns the gene IL6 and congenital rubella syndrome.